Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence

Show more: Authors information and Publication history
Authors Information

1Institute of Clinical Physiology-National Research Council of Italy (IFC-CNR), Pisa, Italy
2Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari Aldo Moro, Bari, Italy
3Allergology Clinic, Clinica San Carlo, Paderno Dugnano, Milan, Italy
4ImmunoAllergology Unit, Careggi University Hospital of Florence, Florence, Italy
5Allergy Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy
6School and Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy


Published online: 26 february 2020
Accepted: 20 February 2020
Received: 2 February 2020


A systematic review of the current literature on retreatment with omalizumab of patients with relapsing chronic spontaneous urticaria was performed. Published evidence shows that retreatment is safe and clinically effective, and that time to complete clinical response reduces as the number of retreatments increases.

Chronic urticaria; Omalizumab; retreatment; therapy

Table of Content: Vol. 52 (No. 4) 2020 July

European Annals of Allergy and Clinical Immunology ISSN 1764-1489 | © 2024